Asset Turnover is linked to ROE % through Du Pont Formula. Japan Tissue Engineering Co's annualizedROE % for the quarter that ended in Mar. 2026 was -13.79%. It is also linked to ROA % through Du Pont Formula. Japan Tissue Engineering Co's annualizedROA % for the quarter that ended in Mar. 2026 was -12.33%.
Japan Tissue Engineering Co (TSE:7774) Asset Turnover Explanation
Asset Turnover is linked to ROE % through Du Pont Formula.
Japan Tissue Engineering Co's annulizedROE % for the quarter that ended in Mar. 2026 is
Note:
The Net Income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
Japan Tissue Engineering Co's annulizedROA % for the quarter that ended in Mar. 2026 is
Note:
The Net Income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
Japan Tissue Engineering Co Asset Turnover Related Terms
Japan Tissue Engineering Co Asset Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7774 vs VRTX, REGN, ALNY: Asset Turnover Comparison
For the Biotechnology subindustry, Japan Tissue Engineering Co's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Japan Tissue Engineering Co Asset Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Japan Tissue Engineering Co's Asset Turnover distribution charts can be found below:
* The bar in red indicates where Japan Tissue Engineering Co's Asset Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
Japan Tissue Engineering Co (TSE:7774) has a Asset Turnover of 0.20 as of Mar. 2026. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Japan Tissue Engineering Co and its competitors.
Is Japan Tissue Engineering Co's Asset Turnover too high?
Japan Tissue Engineering Co's current Asset Turnover is 0.20. Overall, Japan Tissue Engineering Co has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Japan Tissue Engineering Co's Asset Turnover compare to VRTX and REGN?
Japan Tissue Engineering Co's Asset Turnover of 0.20 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Biotechnology company?
A good Asset Turnover depends on the Biotechnology industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Japan Tissue Engineering Co and its competitors. Japan Tissue Engineering Co's current Asset Turnover is 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Japan Tissue Engineering Co stock overvalued right now?
Based on GuruFocus' analysis, Japan Tissue Engineering Co (TSE:7774) is currently considered Modestly Overvalued. The stock's GF Value™ is 円517.18, compared to a current price of 円630.00 — trading 21.8% above its estimated fair value. The current Asset Turnover is 0.20. Japan Tissue Engineering Co's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Japan Tissue Engineering Co (TSE:7774), the current Asset Turnover is 0.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Japan Tissue Engineering Co (TSE:7774) Overvalued in 2026?
Based on GuruFocus' analysis, Japan Tissue Engineering Co stock appears to be overvalued.
The current stock price of 円630.00 is trading 21.8% above its estimated GF Value™ of 円517.18.
GuruFocus considers Japan Tissue Engineering Co to be Modestly Overvalued.
Key valuation signals for TSE:7774:
Asset Turnover: 0.20
GF Value™: 円517.18 vs. price of 円630.00 (21.8% above fair value)
No single metric tells the full story. See the TSE:7774 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Japan Tissue Engineering Co Ltd is a bio-venture enterprise. It is engaged in the development, manufacture, and sale of tissue-engineered medical products and related products. It operates through the Regenerative Medicine, and Research and Development support business segments. The main business goal is to use autologous culturing techniques to develop tissue-engineered medical products and then to manufacture and sell these same tissue-engineered products to medical institutions for medical treatment. The company's tissue-engineered medical products are used in autologous transplant cases, where living cells are taken from the actual patient himself, cultured and then transplanted back to that same patient.
60GF Score
Get the complete analysis for TSE:7774
Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7774 has been successfully added to your 
